Navigation Links
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Date:12/21/2007

s not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from phase 2 and 3 studies of single- agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
2. Synova Healthcare to Participate in Womens Health Care in the New Millennium Conference, as Retail Distribution for the Fem-V(R) Test Kit Expands
3. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
4. 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
5. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
10. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 (HealthDay News) -- Regularly checking the ... stroke, researchers report. "Screening pulse is the method ... over age 65 who have never had a stroke. ... noninvasive and easy way to identify people who might ... said study author Dr. Bernd Kallmunzer, of Erlangen University ...
(Date:7/23/2014)... Officials from China,s Northwest Agricultural and Forestry University in ... signed a memorandum of agreement that lays the groundwork ... Safety in China. , The signing ceremony was held ... between high-level officials of the U.S. Department of Agriculture ... agreement is a landmark event for UC Davis and ...
(Date:7/23/2014)... Coral, FL (PRWEB) July 23, 2014 Rich ... announce the success of their charity yard sale to support ... was raised and 100% of the proceeds will be donated ... at the event are being donated to the Habitat for ... Fort Myers, Florida 33903. , One of the highlights ...
(Date:7/23/2014)... 23, 2014 Global Cardio Care, Inc., ... External Counterpulsation (EECP), is celebrating the 100th birthday ... at the health center. , Weber has been ... receiving ongoing EECP therapy since 1999, he no longer ... CEO of Global Cardio Care, introduced the Sara ...
(Date:7/23/2014)... 23, 2014 Bodybuilding.com, the Internet’s most-visited ... of nutritional supplements, has officially opened the polls for ... , the fastest growing sports nutrition company, is up ... of the Year, Best Tasting Protein of the Year- ... of the year - Whey-HD™, Pre-workout Supplement of the ...
Breaking Medicine News(10 mins):Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3
... born children can also lead normal lives in a ... the McMaster University’s Saroj Saigal. Where educational achievements are ... who were born prematurely, and those with a normal ... greater risk of problems in behavior and academic achievement. ...
... a person was used as a basis to judge the ... report published in the Journal of the American Medical Association. ... that of their Indian and White compatriots, where HIV and ... said to have been implemented by the South African National ...
... failure following use of the drug aprotinin, marketed as ... the drug in heart surgery patients.// The clotting drug ... undergoing cardiac surgery. ,It has now been ... were twice as likely to develop kidney failure and ...
... Global Health Program, founded by Bill and Melinda Gates, ... Executive Director, according to the Gates foundation Release. Dr ... GlaxoSmithKline, will now lead the program. ,Yamada’s key ... while also working on enhancing the availability of drugs ...
... of Medical Research, Sydney have expressed hope over their ... rheumatoid arthritis. //It is also claimed to improve the ... attack, sepsis, psoriasis and post transplant recipients. ... models (mice) and promising results have been obtained. It ...
... unscientific fears, according to a skier who is on a ... a report which states that second hand smoke (SHS) does ... smokers consider the measures as attempts by the powerful antismoking ... ,The Utah Legislature is bei9ng called upon to counter ...
Cached Medicine News:Health News:Safety Of Heart Drug Questioned 2
(Date:7/23/2014)... 2014  The management team at Columbia Laboratories, ... a conference call on July 31, 2014, to ... June 30, 2014.  The call details are as ... am EDTDial-in numbers: , Toll free: (877) 870-4263 ... & archive): , www.columbialabs.com , under ,Investor, ...
(Date:7/23/2014)...  Silk Road Medical, Inc., a developer of ... and extra-cranial cerebrovascular disease, announced today the appointment ... position of Chief Technology Officer.  In this new ... Development efforts across its family of transcarotid access ... joining Silk Road Medical, Michael was the Vice ...
(Date:7/23/2014)... July 23, 2014  Dompe, a leader in R&D for ... that rhNGF (Recombinant Human Nerve Growth Factor) has been designated ... Administration (FDA). The candidate drug, developed by ... drug for the treatment of neurotrophic keratitis, a degenerative corneal ... and is currently without a cure. This is the ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
... N.C., July 27 Timothy Mastro,MD, FACP, DTM&H, ... 1st,as Senior Director of Research, will share information ... prevention at the,International AIDS Conference in Mexico City., ... Planned Trials," will examine ongoing and upcoming clinical ...
... BIRMINGHAM, Ala., July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... Phase II study of intravenous (i.v.) peramivir administered ... for the treatment of seasonal,influenza. The trial, conducted ... met its primary endpoint of improvement in the ...
Cached Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
... The only portable 36/70 static/kinetic/multi-color perimeter that ... room and costs only slightly more than ... perimeter,The Centerfield automatically performs static and kinetic ... to 70 with a fixation shift. Offers ...
... Wavefront Analyzer provides the practitioner with ... analysis system on the market today! ... auto refractometer, auto keratometer, and a ... benefits of wavefront measurement!, ,The KR-9000PW ...
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
Medicine Products: